Cited by 353

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

Progress in biopharmaceutical development

Open access

Kesik‐Brodacka, Malgorzata·2018·Biotechnology and Applied Biochemistry

Open this paper in CoChat — free account

Abstract

Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine. In recent years, the biopharmaceuticals market has developed much faster than the market for all drugs and is believed to have great potential for further dynamic growth because of the tremendous demand for these drugs. Biobetters, which contain altered active pharmaceutical ingredients with enhanced efficacy, will play an important role in the development of biopharmaceuticals. Another significant group of biopharmaceuticals are biosimilars. Their introduction in the European Union and, recently, the Unites States markets will reduce the costs of biopharmaceutical treatment. This review highlights recent progress in the field of biopharmaceutical development and issues concerning the registration of innovative biopharmaceuticals and biosimilars. The leading class of biopharmaceuticals, the current biopharmaceuticals market, and forecasts are also discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/bab.1617

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Structure and chemistry of cytochrome p450
Denisov, I. G., Makris, T. M., Sligar, S. G., & Schlichting, I. (2005) · Chemical Reviews · doi:10.1021/cr0307143 · Cited by 2,106
The Future of Peptide‐based Drugs
Craik, D. J., Fairlie, D. P., Liras, S., & Price, D. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 1,979
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing
Pizza, M., Scarlato, V., Masignani, V., Giuliani, M. M., Aricò, B., Comanducci, M., Jennings, G. T., Baldi, L., Bartolini, E., Capecchi, B., et al. (2000) · Science · doi:10.1126/science.287.5459.1816 · Cited by 1,399
The therapeutic monoclonal antibody market
Ecker, D. M., Jones, S. D., & Levine, H. L. (2015) · mAbs · doi:10.4161/19420862.2015.989042 · Cited by 1,286
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Applications of CRISPR technologies in research and beyond
Barrangou, R., & Doudna, J. A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3659 · Cited by 1,005
Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production
Ahmad, M., Hirz, M., Pichler, H., & Schwab, H. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5732-5 · Cited by 989
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection
Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C.-J., Kanekiyo, M., Kong, W.-P., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 699
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Bispecific antibodies
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
Proof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Didierlaurent, A. M., Laupèze, B., Di Pasquale, A., Hergli, N., Collignon, C., & Garçon, N. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1213632 · Cited by 516
Is the oral route possible for peptide and protein drug delivery?
Morishita, M., & Peppas, N. A. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.08.005 · Cited by 515
Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
Dumont, J., Euwart, D., Mei, B., Estes, S., & Kshirsagar, R. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1084266 · Cited by 483
Construction and Characterization of Virus-Like Particles: A Review
Zeltins, A. (2013) · Molecular Biotechnology · doi:10.1007/s12033-012-9598-4 · Cited by 478
Introduction to current and future protein therapeutics: A protein engineering perspective
Carter, P. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.02.013 · Cited by 467
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
Strohl, W. R. (2015) · BioDrugs · doi:10.1007/s40259-015-0133-6 · Cited by 461
Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer
LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444
Dual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats
Khawli, L. A., Goswami, S., Hutchinson, R., Kwong, Z. W., Yang, J., Wang, X., Yao, Z., Sreedhara, A., Cano, T., Tesar, D. B., et al. (2010) · mAbs · doi:10.4161/mabs.2.6.13333 · Cited by 419
Microscale to manufacturing scale‐up of cell‐free cytokine production—a new approach for shortening protein production development timelines
Zawada, J. F., Yin, G., Steiner, A. R., Yang, J., Naresh, A., Roy, S. M., Gold, D. S., Heinsohn, H. G., & Murray, C. J. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23103 · Cited by 412
CRISPR gene-editing tested in a person for the first time
Cyranoski, D. (2016) · Nature · doi:10.1038/nature.2016.20988 · Cited by 362
Therapeutic Proteins
Dimitrov, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 347
Recombinant pharmaceuticals from microbial cells: a 2015 update
Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016) · Microbial Cell Factories · doi:10.1186/s12934-016-0437-3 · Cited by 339
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
Vaccines, new opportunities for a new society
Rappuoli, R., Pizza, M., Del Giudice, G., & De Gregorio, E. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402981111 · Cited by 335
Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives
Baeshen, M. N., Al-Hejin, A. M., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A. I., Saini, K. S., Baeshen, N. A., & Redwan, E. M. (2015) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1412.12079 · Cited by 330
The state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
Biosimilars: the science of extrapolation
Weise, M., Kurki, P., Wolff-Holz, E., Bielsky, M.-C., & Schneider, C. K. (2014) · Blood · doi:10.1182/blood-2014-06-583617 · Cited by 307
Toll‐like receptors: the swiss army knife of immunity and vaccine development
Dowling, J. K., & Mansell, A. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.22 · Cited by 273
Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products
Aiuti, A., Roncarolo, M. G., & Naldini, L. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707573 · Cited by 264
Cell‐Free Protein Synthesis: Pros and Cons of Prokaryotic and Eukaryotic Systems
Zemella, A., Thoring, L., Hoffmeister, C., & Kubick, S. (2015) · ChemBioChem · doi:10.1002/cbic.201500340 · Cited by 257
China approves first gene therapy
Pearson, S., Jia, H., & Kandachi, K. (2004) · Nature Biotechnology · doi:10.1038/nbt0104-3 · Cited by 255
Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody
Vlasak, J., Bussat, M. C., Wang, S., Wagner-Rousset, E., Schaefer, M., Klinguer-Hamour, C., Kirchmeier, M., Corvaïa, N., Ionescu, R., & Beck, A. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.05.043 · Cited by 252
Plants as Factories for Human Pharmaceuticals: Applications and Challenges
Yao, J., Weng, Y., Dickey, A., & Wang, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226122 · Cited by 252
The economics of biosimilars.
Blackstone, E. A., & Joseph, P. F. (2013) · PubMed · Cited by 233
Biosimilars—why terminology matters
Weise, M., Bielsky, M.-C., De Smet, K., Ehmann, F., Ekman, N., Narayanan, G., Heim, H.-K., Heinonen, E., Ho, K., Thorpe, R., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1936 · Cited by 212
Substrate Oxidation by Cytochrome P450 Enzymes
Ortiz de Montellano, P. R., & De Voss, J. J. (2005) · Cytochrome P450 · doi:10.1007/0-387-27447-2_6 · Cited by 209
Immunogenicity of biopharmaceuticals
Kessler, M., Goldsmith, D., & Schellekens, H. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl476 · Cited by 209
Immunological mechanism underlying the immune response to recombinant human protein therapeutics
Sauerborn, M., Brinks, V., Jiskoot, W., & Schellekens, H. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.11.001 · Cited by 207
(Re)defining biopharmaceutical
Rader, R. A. (2008) · Nature Biotechnology · doi:10.1038/nbt0708-743 · Cited by 201
Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics
Dormitzer, P. R., Suphaphiphat, P., Gibson, D. G., Wentworth, D. E., Stockwell, T. B., Algire, M. A., Alperovich, N., Barro, M., Brown, D. M., Craig, S., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006368 · Cited by 196
Plant-produced biopharmaceuticals: A case of technical developments driving clinical deployment
Lomonossoff, G. P., & D’Aoust, M.-A. (2016) · Science · doi:10.1126/science.aaf6638 · Cited by 194
Large‐scale production of pharmaceutical proteins in plant cell culture—the protalix experience
Tekoah, Y., Shulman, A., Kizhner, T., Ruderfer, I., Fux, L., Nataf, Y., Bartfeld, D., Ariel, T., Gingis–Velitski, S., Hanania, U., et al. (2015) · Plant Biotechnology Journal · doi:10.1111/pbi.12428 · Cited by 193
Cell-free synthetic biology: Engineering in an open world
Lu, Y. (2017) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2017.02.003 · Cited by 167
Immunogenicity of recombinant human proteins: causes and consequences
Schellekens, H., & Casadevall, N. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1202-9 · Cited by 158
Subunit Vaccines of the Future: the Need for safe, Customized and Optimized Particulate Delivery Systems
Foged, C. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.68 · Cited by 154
First plant-made biologic approved
Fox, J. L. (2012) · Nature Biotechnology · doi:10.1038/nbt0612-472 · Cited by 150
Escherichia coli-derived virus-like particles in vaccine development
Huang, X., Wang, X., Zhang, J., Xia, N., & Zhao, Q. (2017) · npj Vaccines · doi:10.1038/s41541-017-0006-8 · Cited by 149
Over‐expression of secreted proteins from mammalian cell lines
Dalton, A. C., & Barton, W. A. (2014) · Protein Science · doi:10.1002/pro.2439 · Cited by 144
Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections
Nuccitelli, A., Cozzi, R., Gourlay, L. J., Donnarumma, D., Necchi, F., Norais, N., Telford, J. L., Rappuoli, R., Bolognesi, M., Maione, D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106590108 · Cited by 142
Current methods for the synthesis of homogeneous antibody–drug conjugates
Sochaj, A. M., Świderska, K. W., & Otlewski, J. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.05.001 · Cited by 142
Bispecific Antibodies for Cancer Immunotherapy: Current Perspectives
Müller, D., & Kontermann, R. E. (2010) · BioDrugs · doi:10.2165/11530960-000000000-00000 · Cited by 137
Robust production of recombinant phosphoproteins using cell-free protein synthesis
Oza, J. P., Aerni, H. R., Pirman, N. L., Barber, K. W., ter Haar, C. M., Rogulina, S., Amrofell, M. B., Isaacs, F. J., Rinehart, J., & Jewett, M. C. (2015) · Nature Communications · doi:10.1038/ncomms9168 · Cited by 125
In Vitro and In Vivo Evaluation of Cysteine and Site Specific Conjugated Herceptin Antibody-Drug Conjugates
Jackson, D., Atkinson, J., Guevara, C. I., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083865 · Cited by 122
Biosimilar, biobetter and next generation therapeutic antibodies
Beck, A. (2011) · mAbs · doi:10.4161/mabs.3.2.14785 · Cited by 106
The transgenic animal platform for biopharmaceutical production
Bertolini, L. R., Meade, H., Lazzarotto, C. R., Martins, L. T., Tavares, K. C. S., Bertolini, M., & Murray, J. D. (2016) · Transgenic Research · doi:10.1007/s11248-016-9933-9 · Cited by 102
TB vaccine development and the End TB Strategy: importance and current status
Fletcher, H. A., & Schrager, L. K. (2016) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trw016 · Cited by 93
Biosimilars: Company Strategies to Capture Value from the Biologics Market
Calo-Fernández, B., & Martinez-Hurtado, J. L. (2012) · Pharmaceuticals · doi:10.3390/ph5121393 · Cited by 92
Optimization of the Bacterial Cytochrome P450 BM3 System for the Production of Human Drug Metabolites
Nardo, G. D., & Gilardi, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131215901 · Cited by 89
A review of blinatumomab, a novel immunotherapy
Newman, M. J., & Benani, D. J. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215618770 · Cited by 84
Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller, D., & Kontermann, R. E. (2007) · PubMed · Cited by 82
Sophisticated Cloning, Fermentation, and Purification Technologies for an Enhanced Therapeutic Protein Production: A Review
Gupta, S. K., & Shukla, P. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00419 · Cited by 82
Engineering human cytochrome P450 enzymes into catalytically self-sufficient chimeras using molecular Lego
Dodhia, V. R., Fantuzzi, A., & Gilardi, G. (2006) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-006-0144-3 · Cited by 80
Setting the stage for biosimilar monoclonal antibodies
Schneider, C. K., Vleminckx, C., Gravanis, I., Ehmann, F., Trouvin, J., Weise, M., & Thirstrup, S. (2012) · Nature Biotechnology · doi:10.1038/nbt.2447 · Cited by 77
Cell-free methods to produce structurally intact mammalian membrane proteins
Shinoda, T., Shinya, N., Ito, K., Ishizuka‐Katsura, Y., Ohsawa, N., Terada, T., Hirata, K., Kawano, Y., Yamamoto, M., Tomita, T., et al. (2016) · Scientific Reports · doi:10.1038/srep30442 · Cited by 74
New Insights into Cell Culture Technology
Gowder, S. J. (2017) · InTech eBooks · doi:10.5772/62590 · Cited by 67
Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes
Nardo, G. D., Fantuzzi, A., Sideri, A., Panicco, P., Sassone, C., Giunta, C., & Gilardi, G. (2007) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-006-0188-4 · Cited by 66
Mammalian Cell Line Developments in Speed and Efficiency
Estes, S. D., & Melville, M. W. (2013) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2013_260 · Cited by 65
Sipuleucel-T
Plosker, G. L. (2010) · Drugs · doi:10.2165/11206840-000000000-00000 · Cited by 61
The regulatory framework of biosimilars in the European Union
Minghetti, P., Rocco, P., Cilurzo, F., Vecchio, L. D., & Locatelli, F. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.001 · Cited by 55
Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7–9th Sep 2015
Giersing, B. K., Modjarrad, K., Kaslow, D. C., Moorthy, V., Bavdekar, A., Cichutek, K., Cravioto, A., Fritzell, B., Graham, B. S., Karron, R. A., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.078 · Cited by 54
Early Insights from Commercialization of Gene Therapies in Europe
Touchot, N., & Flume, M. (2017) · Genes · doi:10.3390/genes8020078 · Cited by 53
Biosimilars: Current perspectives and future implications
Misra, M. (2012) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.91859 · Cited by 49
Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'.
Chamarthy, M. R. K., Williams, S. C., & Moadel, R. M. (2011) · Europe PMC (PubMed Central) · Cited by 46
Human Cytochrome P450 3A4 as a Biocatalyst: Effects of the Engineered Linker in Modulation of Coupling Efficiency in 3A4-BMR Chimeras
Degregorio, D., D'Avino, S., Castrignanò, S., Nardo, G. D., Sadeghi, S. J., Catucci, G., & Gilardi, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00121 · Cited by 38
Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma
Bodet‐Milin, C. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00177 · Cited by 36
Identification of Mutant Asp251Gly/Gln307His of Cytochrome P450 BM3 for the Generation of Metabolites of Diclofenac, Ibuprofen and Tolbutamide
Tsotsou, G. E., Sideri, A., Goyal, A., Nardo, G. D., & Gilardi, G. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201102470 · Cited by 35
Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
Wang, Y.-J., Li, Y., Liu, X., Lu, X., Cao, X., & Jiao, B. (2017) · Marine Drugs · doi:10.3390/md15010018 · Cited by 34
Insights into regioselective metabolism of mefenamic acid by cytochrome P 450 BM 3 mutants through crystallography, docking, molecular dynamics, and free energy calculations
Capoferri, L., Leth, R., ter Haar, E., Mohanty, A. K., Grootenhuis, P. D. J., Vottero, E., Commandeur, J. N. M., Vermeulen, N. P. E., Jørgensen, F. S., Olsen, L., et al. (2016) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24985 · Cited by 31
Sipuleucel-T in Metastatic Castration-Resistant Prostate Cancer†
Plosker, G. L. (2011) · BioDrugs · doi:10.2165/11207140-000000000-00000 · Cited by 31
First malaria vaccine receives positive scientific opinion from EMA
(2015) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2015.20069061 · Cited by 29
Gene therapy as a new treatment option for inherited monogenic diseases
Boudes, P. F. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.009 · Cited by 28
Subtle structural changes in the Asp251Gly/Gln307His P450 BM3 mutant responsible for new activity toward diclofenac, tolbutamide and ibuprofen
Nardo, G. D., Dell’Angelo, V., Catucci, G., Sadeghi, S. J., & Gilardi, G. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.12.005 · Cited by 27
World TB Day 2017: Advances, Challenges and Opportunities in the “End-TB” Era
Petersen, E., Maeurer, M. J., Marais, B. J., Migliori, G. B., Mwaba, P., Ntoumi, F., Vilaplana, C., Kim, K., Schito, M. L., & Zumla, A. I. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.02.012 · Cited by 27
First gene therapy approved
Moran, N. (2012) · Nature Biotechnology · doi:10.1038/nbt1212-1153 · Cited by 26
Electrochemical Detection of Human Cytochrome P450 2A6 Inhibition: A Step toward Reducing Dependence on Smoking
Castrignanò, S., Ortolani, A., Sadeghi, S. J., Nardo, G. D., Allegra, P., & Gilardi, G. (2014) · Analytical Chemistry · doi:10.1021/ac4041839 · Cited by 15
A universal flu vaccine.
Kęsik-Brodacka, M., & Płucienniczak, G. (2014) · Acta Biochimica Polonica · doi:10.18388/abp.2014_1874 · Cited by 10
Electrochemistry of Canis familiaris cytochrome P450 2D15 with gold nanoparticles: An alternative to animal testing in drug discovery
Rua, F., Sadeghi, S. J., Castrignanò, S., Valetti, F., & Gilardi, G. (2015) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2015.03.012 · Cited by 9
Interferon-induced thrombotic microangiopathy
George, J. N. (2016) · Blood · doi:10.1182/blood-2016-10-742759 · Cited by 7
Untitled work
(2013) · PubMed

Engineered living biomaterials
Rodrigo-Navarro, A., Sankaran, S., Dalby, M. J., del Campo, A., & Salmeron-Sanchez, M. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00350-8 · Cited by 494
Mammalian cell culture for production of recombinant proteins: a review of the critical steps in their biomanufacturing
O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 277
Recent advancements in the genetic engineering of microalgae
Sproles, A. E., Fields, F. J., Smalley, T. N., Le, C. H., Badary, A., & Mayfield, S. P. (2021) · Algal Research · doi:10.1016/j.algal.2020.102158 · Cited by 228
Three Decades of Research on Recombinant Collagens: Reinventing the Wheel or Developing New Biomedical Products?
Fertala, A. (2020) · Bioengineering · doi:10.3390/bioengineering7040155 · Cited by 109
Current advances in the algae-made biopharmaceuticals field
Rosales-Mendoza, S., Solís-Andrade, K. I., Márquez-Escobar, V. A., González-Ortega, O., & Bañuelos-Hernandez, B. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1739643 · Cited by 55

See all 353

Authors: Kesik‐Brodacka, M.
Venue: Biotechnology and Applied Biochemistry
Publisher: Wiley
Published: 2017-11-02
Volume: 65
Issue: 3
Pages: 306-322
ISSN: 0885-4513 (ISSN-L)
1470-8744
DOI: 10.1002/bab.1617
OpenAlex: W2763110750
Cited by: 353
References: 98
FWCI: 4.71
Type: journal article
Language: en
Open access: hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Progress in biopharmaceutical development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources